Jaguar Gene Therapy launches, targeting rare genetic diseases

By The Science Advisory Board staff writers

February 25, 2021 -- Jaguar Gene Therapy has launched after being in stealth mode with the goal of accelerating the development, manufacturing, and commercialization of novel gene therapy treatments for patients with severe genetic diseases.

The company, which has been operating in stealth mode for the past year, is focused on advancing its preclinical pipeline of gene therapies based on adeno-associated virus 9 (AAV9). The company is targeting diseases with significant unmet needs such as galactosemia, genetic causes of autism spectrum disorder, type 1 diabetes, and Bardet-Biedl syndrome (BBS).

AXV101, a candidate for BBS1, a subset of Bardet-Biedl syndrome, is being developed by Axovia Therapeutics, a majority-owned subsidiary of Jaguar Gene Therapy.

The new venture was created in collaboration with Deerfield Management, which funded the series A financing and helped establish academic collaborations for pipeline projects. Through Deerfield, Jaguar has access to an existing network of 18 key academic institutions.

Provention Bio's bispecific antibody boosts gene therapy safety in mice
Provention Bio has released results from a preclinical proof-of-concept study for its bispecific antibody-based molecule, PRV-3279, conducted in mouse...
AllStripes, Taysha Gene Therapies partner on rare disease gene therapy program
AllStripes and Taysha Gene Therapies have entered a multiyear collaboration focused on advancing the development of TSHA-104, an adeno-associated virus...
Prevail Therapeutics granted gene therapy patent
The U.S. Patent and Trademark Office has issued a composition of matter patent (No. 10,837,028) to Prevail Therapeutics for its adeno-associated viral...
Taysha nabs rare pediatric disease, orphan drug status
Taysha Gene Therapies has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration for TSHA-104,...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter